Loading stock data…
PHVS
$29.44-1.57 (-5.06%)
Market ClosedLast close May 1
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Pharvaris N.V. in the Healthcare sector is trading at $29.44. The stock is currently near its 52-week high of $31.14, remaining 17.8% above its 200-day moving average. Technical signals show neutral RSI of 56 and bullish MACD crossover, explaining why PHVS maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 56) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$29.44
Potential Upside
5%
Whystock Fair Value$30.91
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus13 analysts
Mean target$46.71+58.7%
Range$30.15 – $75.18
Fundamentals
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.96B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-2.58
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-64.77%
Volume
Today's trading volume
512,196
Recent News
For Pharvaris Investors, the Director's Sale Matters Less Than What's Coming Next
This biopharma innovator in rare disease therapies reported a notable insider sale amid a year of strong stock performance.
KalVista Scores $1.9 Billion Takeover Deal; Why A Key Rival Jumped Too
Shares of KalVista Pharmaceuticals catapulted Wednesday on a $1.9 billion takeover offer from Italy's Chiesi Group.
Pharvaris' CEO Dumped Over 23,000 Company Shares. Here's What That Means for Investors.
This clinical-stage biotech focused on rare disease therapies reported a notable insider sale amid a year of sharp share price gains.
Texas Instruments upgraded, Circle downgraded: Wall Street's top analyst calls
Texas Instruments upgraded, Circle downgraded: Wall Street's top analyst calls
Did Phase 3 Completion and 2025 Losses Just Shift Pharvaris’ (PHVS) Investment Narrative?
Pharvaris N.V. reported full-year 2025 results, posting a net loss of €175.7 million and a basic loss per share from continuing operations of €2.97, widening from the prior year. Alongside these results, the company highlighted progress in its hereditary angioedema pipeline, including completed Phase 3 enrollment and confirmed plans to file a New Drug Application for deucrictibant immediate-release in the first half of 2026. We will now examine how Pharvaris’s completed Phase 3 enrollment...